Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis
Montreal Neurological Institute and Hospital · Douglas Mental Health University Institute · +84 more institutions
Abstract
Multifactorial mechanisms underlying late-onset Alzheimer's disease (LOAD) are poorly characterized from an integrative perspective. Here spatiotemporal alterations in brain amyloid-β deposition, metabolism, vascular, functional activity at rest, structural properties, cognitive integrity and peripheral proteins levels are characterized in relation to LOAD progression. We analyse over 7,700 brain images and tens of plasma and cerebrospinal fluid biomarkers from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Through a multifactorial data-driven analysis, we obtain dynamic LOAD-abnormality indices for all biomarkers, and a tentative temporal ordering of disease progression. Imaging results suggest that…
Citation impact
- FWCI
- 55.52
- Percentile
- 100%
- References
- 70
Authors
316- YIYasser Iturria‐MedinaCorresponding
Montreal Neurological Institute and Hospital, Douglas Mental Health University Institute
- RCRoberto C. Sotero
University of Calgary
- PTP.-J. Toussaint
Montreal Neurological Institute and Hospital, Douglas Mental Health University Institute
- JMJ.M. Mateos-Pérez
Montreal Neurological Institute and Hospital, Douglas Mental Health University Institute
- ACAlan C. Evans
Montreal Neurological Institute and Hospital, Douglas Mental Health University Institute
Topics & keywords
- Abnormality
- Disease
- Neuroimaging
- Neuroscience
- Pathological
- Medicine
- Alzheimer's disease
- Amyloid (mycology)
- Good health and well-being
Funding
- UDU.S. Department of DefenseAwards: U01 AG024904, W81XWH, W81XWH-12-2-, W81XWH-12-2-0012, AG024904
- FFFoundation for the National Institutes of HealthAwards: W81XWH-12-2-0012, Grant U01 AG024904, AG024904, U01 AG024904
- AAAlzheimer's AssociationAwards: U01 AG024904, W81XWH-12-2-0012
- BSBristol-Myers SquibbAwards: U01 AG024904, AG024904, W81XWH-12-2-0012
- ELEli Lilly and CompanyAwards: U01 AG024904, AG024904, W81XWH-12-2-0012
- PPfizerAwards: AG024904, W81XWH-12-2-0012, U01 AG024904
- BBiogenAwards: W81XWH-12-2-0012, U01 AG024904, AG024904
- UOUniversity of Southern CaliforniaAwards: W81XWH-12-2-0012, U01 AG024904
- FHF. Hoffmann-La RocheAwards: W81XWH-12-2-0012, AG024904, U01 AG024904
- MSMeso Scale DiagnosticsAwards: U01 AG024904, AG024904, W81XWH-12-2-0012
- ADAlzheimer's Disease Neuroimaging InitiativeAwards: AG024904, W81XWH-12-2-, W81XWH-12-2-0012, Department of Defense award number W81XWH-12-2-0012, U01 AG024904
- BBioClinicaAwards: U01 AG024904, W81XWH-12-2-0012, AG024904
- NPNovartis Pharmaceuticals CorporationAwards: W81XWH-12-2-0012, U01 AG024904, AG024904
- FBFondation Brain Canada
- NCNorthern California Institute for Research and EducationAwards: U01 AG024904, W81XWH-12-2-0012
- EEisaiAwards: W81XWH-12-2-0012, U01 AG024904, AG024904
- AFAzrieli FoundationAward: BC_Azrieli_MIRI_3388
- SServierAwards: AG024904, W81XWH-12-2-0012, U01 AG024904
- HLH. Lundbeck A/SAwards: U01 AG024904, AG024904, W81XWH-12-2-0012
- IIXICOAwards: AG024904, W81XWH-12-2-0012, U01 AG024904
- NINational Institutes of HealthAwards: AG024904, U01 AG024904, W81XWH, Grant U01 AG024904, W81XWH-12-2-0012
- GGenentechAwards: W81XWH-12-2-0012, AG024904, U01 AG024904
- UOUniversity of California, San Diego
- CICanadian Institutes of Health ResearchAwards: U01 AG024904, W81XWH-12-2-0012
- NINational Institute on AgingAwards: U01 AG024904, W81XWH-12-2-0012, AG024904
- NINational Institute of Biomedical Imaging and BioengineeringAwards: W81XWH-12-2-0012, U01 AG024904, AG024904